Karine Lacombe to Hepatitis C, Chronic
This is a "connection" page, showing publications Karine Lacombe has written about Hepatitis C, Chronic.
Connection Strength
1.700
-
Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J Viral Hepat. 2018 02; 25(2):108-117.
Score: 0.358
-
HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc. 2017 05 15; 20(1):21446.
Score: 0.343
-
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. J Acquir Immune Defic Syndr. 2017 05 01; 75(1):97-107.
Score: 0.342
-
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clin Infect Dis. 2020 05 23; 70(11):2369-2376.
Score: 0.106
-
Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1387-1396.
Score: 0.102
-
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018 12; 62:94-103.
Score: 0.095
-
Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018 09 10; 32(14):1995-2004.
Score: 0.094
-
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Med. 2018 03; 19(3):227-237.
Score: 0.089
-
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals. AIDS. 2017 06 01; 31(9):1223-1234.
Score: 0.086
-
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017 07; 67(1):23-31.
Score: 0.084